This is therapeutically important as, while suppression of mutant K-Ras is not sufficient to downregulate PI3K/AKT, IGF-IR inhibition could suppress PI3K signaling in K-Ras mutated colorectal cancers [168]. The gene discussed is KRAS; the disease is colorectal cancer.